This suggests that the combination treatment may have enhanced the TNFR1 signaling axis to activate the RIPK1/RIPK3 pathway, further driving necroptosis and promoting inflammatory responses within the tumor immune microenvironment (Figure 13F). The gene discussed is TNFRSF1A; the disease is neoplasm.